Efficacy and safety of perampanel as first adjunctive therapy in patients with focal‐onset seizures or generalized tonic‐clonic seizures in four post‐marketing studies across regions

Documenti analoghi

• Long‐term safety and efficacy of adjunctive perampanel in pediatric patients (ages 4 to <12 years) with inadequately controlled focal‐onset seizures or generalized tonic–clonic seizures
  di: Robert Flamini, et al.
  Pubblicazione: (2025)
• Real‐world use of adjunctive perampanel for focal‐onset seizures in Italy: A mirroring clinical practice study of perampanel in adults and adolescents ( AMPA )
  di: Alfredo D'Aniello, et al.
  Pubblicazione: (2025)
• Efficacy and safety of perampanel in patients with seizures associated with Lennox–Gastaut syndrome: A randomized trial
  di: David G. Vossler, et al.
  Pubblicazione: (2024)
• PERPRISE: A prospective non‐interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic–clonic seizures: First interim analysis
  di: Bernhard J Steinhoff, et al.
  Pubblicazione: (2024)
• Long‐term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic–clonic seizures: An open‐label extension trial
  di: David G. Vossler, et al.
  Pubblicazione: (2024)